Corn and ethanol price weakness weighs on Tate & Lyle

Tate's adjusted pre-tax profit in the year to March 31 rose 5% to £193mln on broadly flat sales
Corn and ethanol price weakness weighs on Tate & Lyle
Tate's bulk ingredient (BI) arm boosted adjusted operating profit 1%, although it fell 3% at constant currency

--- Adds further detail, share price and broker comment ---

Tate & Lyle PLC (LON:TATE) reported higher annual profit, although it took a hit from lower corn costs and weak ethanol prices in the US.

Tate's bulk ingredient (BI) arm boosted adjusted operating profit by 1%, although it fell 3% at constant currency as the weaker commodity prices took their toll.

Bulk ingredient volumes grew 3% in 2015/16 as North American bulk corn sweetener volumes rose 1%.

But the robust sweetener demand was almost offset by price weakness in other commodity markets such as ethanol.

The company completed capacity expansion projects for its speciality food ingredient (SFI) business as planned and said its supply chain did better as operational disciplines improved.

Group adjusted pre-tax profit in the year to March 31 rose 5% to £193mln on broadly flat sales of about £2.3bn.

Shares rose 10.2p, or 1.6%, to 624.16p in early London trading.

Liberum Capital said it rated Tate as a 'buy' with a 700p target price.

Russ Mould at AJ Bell said: "Tate & Lyle has recovered from a torrid 2015 following a good performance from its speciality food ingredients business, which makes sugar substitutes."

Shore Capital forecast a return to volume growth across SFI, excluding sucralose and food systems, driven by North America.

It said planned consolidation of sucralose production into one site in Alabama should offset anticipated further volume losses.

In BI, whilst still early in the season, management previously guided to a modest margin benefit following the annual sweetener rounds.

Shore analyst Darren Shirley said: "We retain our 'hold' recommendation, with a more positive stance requiring a leap of faith on sustained SFI delivery that we are not yet confident enough to make."

The company re-aligned its Eaststarch joint venture to increase speciality focus and reduce exposure to regulated markets

It also restructured and positioned its Splenda sucralose arm as a more focused, low-cost and sustainable business.

Tate proposed a final dividend of 19.8p, making an unchanged total dividend of 28p, as previously indicated.

Chief executive Javed Ahmed said: "Both business divisions delivered margin expansion and we completed the major structural change initiatives needed to further strengthen the business and drive higher quality earnings.

"Turning to the outlook for the 2017 financial year, subject to currency movements, we are confident the group will continue to make progress in line with our plan."

View full TATE profile View Profile

Tate & Lyle Timeline

September 23 2014
February 24 2014

Related Articles

April 17 2018
The group's major shareholders have staunchly supported the business while the AIM-listed group sorts out its financial position

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.